Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KHK2455 + mogamulizumab
- Development stage
- Phase 1
- Lead developer
- Kyowa Kirin
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
KHK2455 + mogamulizumab is an investigational combination therapy for cancer. KHK2455 is a novel, selective, oral indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor that targets the IDO-1 apo-enzyme with long-lasting and potent activity. Mogamulizumab is a humanized monoclonal antibody targeting CC chemokine receptor 4 (CCR4), approved for certain T-cell lymphomas and under investigation in other cancers. The combination has shown safety, tolerability, suppression of kynurenine production (a marker of IDO activity), and early antitumor signals in patients with advanced solid tumors in phase 1/2 studies[1][3][4]. Preclinical models suggest synergy between these agents due to their complementary immunomodulatory mechanisms.
- Other names
- mogamulizumab-kpkc
02
Targets
CCR4 (C-C Motif Chemokine Receptor 4)IDO1 (Indoleamine 2,3-dioxygenase 1)
Beyond the preview
Go deeper on KHK2455 + mogamulizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KHK2455 + mogamulizumab.